Oxford Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Oxford Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-426	Closed	-$81K	–	1187
2019 Q4	$81K	Sell	426 -216	-34%	-$42.4K	﹤0.01%	1634
2019 Q3	$124K	Sell	642 -1,563	-71%	-$304K	﹤0.01%	1616
2019 Q2	$378K	Buy	2,205 +1,540	+232%	+$266K	0.01%	1383
2019 Q1	$134K	Buy	+665	New	+$139K	﹤0.01%	1550
2018 Q4	–	Sell	-1,418	Closed	-$338K	–	2091
2018 Q3	$338K	Sell	1,418 -1,955	-58%	-$457K	0.01%	1464
2018 Q2	$899K	Buy	+3,373	New	+$830K	0.02%	1098
2017 Q4	–	Sell	-713	Closed	-$86K	–	1859
2017 Q3	$86K	Buy	713 +217	+44%	+$20.3K	﹤0.01%	1480
2017 Q2	$48K	Buy	+496	New	+$68.6K	﹤0.01%	1430

Other funds holding SYRE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oxford Asset Management's SYRE Position: Q1 2020 in Review

Oxford Asset Management sold out of Spyre Therapeutics (SYRE) in Q1 2020, closing a stake of 426 shares — an estimated $81K sold.

Oxford Asset Management first reported a position in SYRE in Q2 2017 and held it in 8 quarters. The position peaked at $899K in Q2 2018. 70 funds tracked by Wall St. Rank hold SYRE as of Q1 2020.

Oxford Asset Management reported no remaining Spyre Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 426 Spyre Therapeutics shares in Q1 2020, an estimated $81K.
Oxford Asset Management first reported a position in Spyre Therapeutics in Q2 2017 and held it in 8 quarters.
Oxford Asset Management's Spyre Therapeutics position peaked at $899K in Q2 2018.
70 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.